Atyr Pharma, Stock Cash Flow From Operations
| ATYR Stock | 4.72 0.22 4.45% |
Fundamental analysis of ATyr Pharma, allows traders to better anticipate movements in ATyr Pharma,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. aTyr Pharma, Company Cash Flow From Operations Analysis
ATyr Pharma,'s Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current ATyr Pharma, Cash Flow From Operations | (69.12 M) |
Most of ATyr Pharma,'s fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, aTyr Pharma, is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, aTyr Pharma, has (69.12 Million) in Cash Flow From Operations. This is 113.11% lower than that of the Biotechnology sector and 210.55% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 107.12% higher than that of the company.
ATyr Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ATyr Pharma,'s direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ATyr Pharma, could also be used in its relative valuation, which is a method of valuing ATyr Pharma, by comparing valuation metrics of similar companies.ATyr Pharma, is currently under evaluation in cash flow from operations category among its peers.
ATyr Fundamentals
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 376.32 M | ||||
| Shares Outstanding | 89 M | ||||
| Shares Owned By Insiders | 2.23 % | ||||
| Shares Owned By Institutions | 70.50 % | ||||
| Number Of Shares Shorted | 20.38 M | ||||
| Price To Book | 5.86 X | ||||
| Price To Sales | 1,148 X | ||||
| Revenue | 235 K | ||||
| Gross Profit | (52.82 M) | ||||
| EBITDA | (66.37 M) | ||||
| Net Income | (64.02 M) | ||||
| Total Debt | 13.28 M | ||||
| Book Value Per Share | 0.84 X | ||||
| Cash Flow From Operations | (69.12 M) | ||||
| Short Ratio | 5.25 X | ||||
| Earnings Per Share | (0.80) X | ||||
| Target Price | 19.35 | ||||
| Number Of Employees | 56 | ||||
| Beta | 0.9 | ||||
| Market Capitalization | 439.68 M | ||||
| Total Asset | 96.83 M | ||||
| Retained Earnings | (532.05 M) | ||||
| Working Capital | 66.99 M | ||||
| Net Asset | 96.83 M |
About ATyr Pharma, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze aTyr Pharma,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of aTyr Pharma, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ATyr Pharma,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ATyr Pharma, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ATyr Pharma, will appreciate offsetting losses from the drop in the long position's value.Moving together with ATyr Stock
| 0.63 | A | Agilent Technologies Earnings Call This Week | PairCorr |
Moving against ATyr Stock
| 0.75 | ERNA | Eterna Therapeutics | PairCorr |
| 0.69 | CLOV | Clover Health Investments Earnings Call This Week | PairCorr |
| 0.66 | MOLN | Molecular Partners | PairCorr |
| 0.64 | TELO | Telomir Pharmaceuticals, | PairCorr |
| 0.38 | LPCN | Lipocine | PairCorr |
The ability to find closely correlated positions to ATyr Pharma, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ATyr Pharma, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ATyr Pharma, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling aTyr Pharma, to buy it.
The correlation of ATyr Pharma, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ATyr Pharma, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if aTyr Pharma, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ATyr Pharma, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.